SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's pipeline targets conditions with high unmet medical need, including rare pediatric cancers and genetic disorders.
Founded in 2017, SpringWorks has raised significant venture funding to advance its therapeutic programs through clinical development. The company has attracted investment from prominent healthcare-focused venture capital firms and strategic investors in the biotechnology sector. SpringWorks went public on the NASDAQ in 2020, providing additional capital to support its clinical trials and drug development efforts across multiple rare disease indications.
SpringWorks has received investment from 1 venture capital firm.
Clinical-stage biopharmaceutical company developing treatments for rare diseases and cancer.
SpringWorks has received investment from Johnson & Johnson Innovation - JJDC. These venture capital firms and investors provide both capital and strategic support.
SpringWorks operates in the Biotech sector. Clinical-stage biopharmaceutical company developing treatments for rare diseases and cancer.
